Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 10/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25569964 | 1.00 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4ENPC1 | |
| SCHEMBL24548715 | 1.00 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4ENPC1 | |
| SCHEMBL22960797 | 0.98 | TYMP (0.41) | TYMPTAS1R3TAS1R1KDM4ENPC1 | |
| SCHEMBL12513080 | 0.94 | TYMP (0.40) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL15060564 | 0.92 | TYMP (0.39) | TYMPTAS1R3TAS1R1 | |
| SCHEMBL12434625 | 0.92 | TYMP (0.39) | TYMPTAS1R3TAS1R1 | |
| SCHEMBL11943227 | 0.91 | TYMP (0.38) | TYMPTAS1R3TAS1R1NT5E | |
| SCHEMBL916676 | 0.91 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4ENPC1 | |
| SCHEMBL16326506 | 0.89 | TYMP (0.43) | TYMPTAS1R3TAS1R1KDM4EHPGD | |
| SCHEMBL6398167 | 0.88 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322842-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230312635-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230256425-A1 | INORGANIC POROUS SUBSTRATE, INORGANIC POROUS SUPPORT, AND NUCLEIC ACID PRODUCTION METHOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230242570-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230167152-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20220153774-A1 | INORGANIC POROUS CARRIER AND METHOD FOR PRODUCING NUCLEIC ACIDS USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312635-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | POLRMT, RNGTT, POLM | TYMP 88/4885TAS1R3 1150/4885TAS1R1 963/4885 |
| US-20230256425-A1 | INORGANIC POROUS SUBSTRATE, INORGANIC POROUS SUPPORT, AND NUCLEIC ACID PRODUCTION METHOD | DNMT3L, FBL, SIK1 | TYMP 184/4885TAS1R3 1440/4885TAS1R1 933/4885 |
| US-20230167152-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | POLI, POLL, DNMT3A | TYMP 1030/4885TAS1R3 2805/4885TAS1R1 2920/4885 |
| US-20230322842-A1 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | NSUN2, RNGTT, NSUN3 | TYMP 497/4885TAS1R3 1868/4885TAS1R1 998/4885 |
| US-20220153774-A1 | INORGANIC POROUS CARRIER AND METHOD FOR PRODUCING NUCLEIC ACIDS USING SAME | SLCO2A1, SLCO2B1, SLCO4C1 | TYMP 702/4885TAS1R3 1082/4885TAS1R1 619/4885 |
| US-20230242570-A1 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | FBL, POLI, POLL | TYMP 689/4885TAS1R3 1306/4885TAS1R1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.